AU2019410062A1 - Combination treatment for solid tumors using docetaxel and a CYP3A inhibitor - Google Patents
Combination treatment for solid tumors using docetaxel and a CYP3A inhibitor Download PDFInfo
- Publication number
- AU2019410062A1 AU2019410062A1 AU2019410062A AU2019410062A AU2019410062A1 AU 2019410062 A1 AU2019410062 A1 AU 2019410062A1 AU 2019410062 A AU2019410062 A AU 2019410062A AU 2019410062 A AU2019410062 A AU 2019410062A AU 2019410062 A1 AU2019410062 A1 AU 2019410062A1
- Authority
- AU
- Australia
- Prior art keywords
- docetaxel
- cyp3a
- cyp3a inhibitor
- treatment
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2023204693A AU2023204693A1 (en) | 2018-12-21 | 2023-07-14 | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18215488.0 | 2018-12-21 | ||
| EP18215488 | 2018-12-21 | ||
| PCT/EP2019/086125 WO2020127607A1 (en) | 2018-12-21 | 2019-12-18 | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023204693A Division AU2023204693A1 (en) | 2018-12-21 | 2023-07-14 | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019410062A1 true AU2019410062A1 (en) | 2021-08-12 |
Family
ID=64901398
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019410062A Abandoned AU2019410062A1 (en) | 2018-12-21 | 2019-12-18 | Combination treatment for solid tumors using docetaxel and a CYP3A inhibitor |
| AU2023204693A Abandoned AU2023204693A1 (en) | 2018-12-21 | 2023-07-14 | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023204693A Abandoned AU2023204693A1 (en) | 2018-12-21 | 2023-07-14 | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20220071944A1 (https=) |
| EP (1) | EP3897611A1 (https=) |
| JP (3) | JP2022514960A (https=) |
| KR (1) | KR20220004011A (https=) |
| CN (1) | CN113473982A (https=) |
| AU (2) | AU2019410062A1 (https=) |
| BR (1) | BR112021012266A2 (https=) |
| CA (1) | CA3124319C (https=) |
| CL (1) | CL2021001635A1 (https=) |
| IL (1) | IL284225A (https=) |
| MX (1) | MX2021007480A (https=) |
| PE (1) | PE20220129A1 (https=) |
| WO (1) | WO2020127607A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20220250A1 (es) * | 2018-12-21 | 2022-02-16 | Modra Pharmaceuticals B V | Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma |
| GB202201935D0 (en) | 2022-02-14 | 2022-03-30 | Modra Pharmaceuticals B V | Methods and compositions for treating cancer in taxane-resistant patients |
| CN116270617B (zh) * | 2023-03-29 | 2024-01-26 | 济宁医学院附属医院 | Arp2/3复合物抑制剂CK-666和多西他赛组合用于癌症治疗的制药用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9089544B2 (en) * | 2007-08-24 | 2015-07-28 | Slotervaart Participaties Bv | Composition |
| GB0716591D0 (en) * | 2007-08-24 | 2007-10-03 | Vereniging Het Nl Kanker I | Composition |
| MX2010002179A (es) * | 2007-08-24 | 2010-04-27 | Stichting Het Nl Kanker I | Composicion para el tratamiento de enfermedades neoplasicas. |
| JP2012500788A (ja) | 2008-08-22 | 2012-01-12 | スティヒティング ヘット ネーデルランド カンケル インスティテュート | 組成物 |
| PE20220250A1 (es) * | 2018-12-21 | 2022-02-16 | Modra Pharmaceuticals B V | Uso de docetaxel en el tratamiento de cancer mediante control de niveles maximos en plasma |
-
2019
- 2019-12-18 WO PCT/EP2019/086125 patent/WO2020127607A1/en not_active Ceased
- 2019-12-18 CA CA3124319A patent/CA3124319C/en active Active
- 2019-12-18 KR KR1020217022969A patent/KR20220004011A/ko not_active Ceased
- 2019-12-18 CN CN201980090621.4A patent/CN113473982A/zh active Pending
- 2019-12-18 PE PE2021001053A patent/PE20220129A1/es unknown
- 2019-12-18 BR BR112021012266-4A patent/BR112021012266A2/pt not_active Application Discontinuation
- 2019-12-18 AU AU2019410062A patent/AU2019410062A1/en not_active Abandoned
- 2019-12-18 MX MX2021007480A patent/MX2021007480A/es unknown
- 2019-12-18 JP JP2021536396A patent/JP2022514960A/ja active Pending
- 2019-12-18 EP EP19828725.2A patent/EP3897611A1/en active Pending
- 2019-12-18 US US17/416,946 patent/US20220071944A1/en active Pending
-
2021
- 2021-06-18 CL CL2021001635A patent/CL2021001635A1/es unknown
- 2021-06-20 IL IL284225A patent/IL284225A/en unknown
-
2023
- 2023-05-01 JP JP2023075514A patent/JP2023102786A/ja active Pending
- 2023-07-14 AU AU2023204693A patent/AU2023204693A1/en not_active Abandoned
-
2025
- 2025-03-24 JP JP2025049063A patent/JP2025094186A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2025094186A (ja) | 2025-06-24 |
| JP2023102786A (ja) | 2023-07-25 |
| IL284225A (en) | 2021-08-31 |
| BR112021012266A2 (pt) | 2021-08-31 |
| JP2022514960A (ja) | 2022-02-16 |
| EP3897611A1 (en) | 2021-10-27 |
| MX2021007480A (es) | 2021-10-13 |
| CL2021001635A1 (es) | 2022-04-22 |
| CA3124319A1 (en) | 2020-06-25 |
| KR20220004011A (ko) | 2022-01-11 |
| WO2020127607A1 (en) | 2020-06-25 |
| CN113473982A (zh) | 2021-10-01 |
| AU2023204693A1 (en) | 2023-08-10 |
| CA3124319C (en) | 2023-07-04 |
| PE20220129A1 (es) | 2022-01-27 |
| US20220071944A1 (en) | 2022-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250312305A1 (en) | Cancer Treatment Using Docetaxel by Controlling Peak Plasma Levels | |
| AU2023204693A1 (en) | Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor | |
| US20240091194A1 (en) | 6-(2,4-Dichlorophenyl)-5-[4-[(3S)-1-(3-Fluoropropyl)Pyrrolidin-3-Yl]Oxyphenyl]-8,9-Dihydro-7H-Benzo[7]Annulene-2-Carboxylic Acid For Use In Metastatic Or Advanced Breast Cancer Patients | |
| KR20200026969A (ko) | 치료제의 비경구 투여를 위한 조성물 | |
| CN112533610B (zh) | 用于治疗腺样囊性癌的包含双氟烷基-1,4-苯并二氮杂䓬酮化合物的组合物 | |
| TW202337469A (zh) | 治療小細胞肺癌之方法 | |
| TW202302084A (zh) | 以安森司坦和帕博西尼治療乳癌 | |
| EP3854396A1 (en) | Quinoline derivative used for treating small cell lung cancer | |
| EP4385507A1 (en) | Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor | |
| HK40111479A (en) | Combination treatment for solid tumors using cabazitaxel and a cyp3a inhibitor | |
| CN118946350A (zh) | 用于治疗紫杉烷耐药性患者的癌症的方法和组合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |